No. of Recommendations: 1
The window of opportunity to accumulate at $9/share or below was very short lived. I've ended up buying more at around $9.40 post their Q3 earnings, which were very solid. I could have posted about Coloplast (CLPBY) on the Falling Knives board because they are down 30% over the last year. I expect them to make that up and more in the coming year, based on steady and continuing revenue growth in the high single digits, progress on cost reduction, and successful completion of a CEO search. Target price of $15-$20 in a year if all goes well.
